Theme: Insights of Translational research

Translational Medicine 2016

Translational Medicine 2016

Translational Medicine-2016 conference will focus on the latest and exciting innovations in all areas of research offering a unique opportunity for investigators across the globe to meet, network, and perceive new scientific innovations. Translational medicine is a rapidly growing discipline in biomedical research and aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative "bench-to-bedside" approach. . Within public health, translational medicine is focused on ensuring that proven strategies for disease treatment and prevention are actually implemented within the community.

Why to attend???

The Translational Medicine conferences organized by OMICS International aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Translational Medicine. It also provides the chance for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the fields of translational medicine.

Translational Medicine-2016 is an international platform for presenting research about diagnosis, prevention and management and exchanging ideas about it and thus, contributes to the dissemination of knowledge in translational medicine for the benefit of both the academia and business.

This translational medicine workshops also welcomes the participation of Presidents, CEO’s, Delegates and industrial executives from Pharma and Health care sectors making the conference a perfect platform to network, share views and knowledge through interactive keynote, plenary, poster and B2B discussions.

The organizing committee of this medicinal meeting is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Translational Medicine-2016, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Translational Medicine-2016 organizing committee look forward to meeting you in San Francisco, USA.

Targeted Audience:

Translational Research Associates
Clinical Researchers
Oncologist
Hematologist
Clinicians
Students

 

 

 

 

 

OMICS International Conferences invites all the participants from all over the world to attend the”5th International Conference on Translational Medicine” during November 28-30,2016,San Francisco,USA,which includes keynote presentations, Oral talks, Poster presentations and Exhibitions.

Track-1:Biomarkers in Translational  Medicine

Translational medicine is the emerging discipline involving the translation of laboratory findings into the design and implementation of early-stage clinical trials.TM focuses on translating pre-clinical data from in vivo, in vitro, and in silicon research into the clinic to help design trials, determine methods and choose the biomarkers. Biomarkers play a vital role in the development and growth of translational medicine. Predictive biomarkers are the markers which can be used to identify subpopulations of patients who are most likely to respond to a given therapy.

Biomarkers in clinical drug development enable continued clinical development of drugs suspected of human irrelevant animal toxicities– ensuring patient safety, reducing drug failures and loss of time. A genomic biomarker is a measurable DNA or RNA characteristic that is an indicator of normal biologic processes, pathology diagnosis and response to therapeutic or other interventions. Ex: Cancer Biomarker Specific and sensitive mRNA biomarkers are used for the identification of skin in ‘touch DNA’ evidence.

Related Conferences: 7th International Conference on Biomarker and Clinical Research November 28-30 2016, USA; 4th International Conference on Blood Malignancies and Treatment April 18-20 2016, UAE; International Conference and Expo on Molecular and Cancer Biomarkers Sep 15-17 2016, Germany; International Conference and Exhibition on Pediatric Oncology August 04-06 2016, Canada; International Conference on Leukemia and Bone Marrow Transplantation November 10-12 2016, Turkey; Biomarker Summit 2016 March 21-23 2016,USA; International Conference on Biomarker and Clinical Research May 16-17 2016, France; Circulating Biomarker World Congress March 21-22 2016, USA; The Biomarker Conference February 18-19 2016, USA; 2nd Biomarker Conference September 19-20 2016,USA.

Track-2: Translational Research in Blood Disorders

People may be affected by many different types of blood conditions and blood cancers. Common blooddisorders include anemia, Clotting and bleeding disorders such as hemophilia blood clots, and blood cancers such as leukemia, lymphoma, and myelomaClinical research emphasize the paradox that both anemia and transfusion are associated with organ injury and increased morbidity and mortality across a wide span of disease states and surgical interventions. Among  the other blood disorders. Leukemia is the most common form of cancer in children, affecting about 3,000 children each year in the United States, accounting for about 30 percent of childhood cancers.

Functional and translational genomic sequencing will be used to investigate mechanisms of globin gene regulation and proteomics to study the red blood cell membrane function in health and disease. A blood and marrow transplant replaces a person's abnormal stem cells with healthy ones from another person (a donor). This procedure allows the recipient to get new stem cells that work properly.

Related Conferences: 4th International Conference on Blood Malignancies and Treatment April 18-20 2016, UAE; 3rd International Conference on Hematology and Blood Disorders November 02-04 2015,USA; 3rd Indo Global Summit & Expo on Healthcare October 05-07 2015 India; 5th World Congress on Hemophilia June 06-08 2016,UK; 6th International Conference on Hematology and Lymph November 14-16,2016 USA; 10th Dutch Hematology Congress January 20-22 2016, The Netherlands; SCRIPPS Clinical Hematology and Oncology Conference February 13-16 2016 USA; 31st Belgian Hematological Annual Meeting January 29-30 2016 Belgium; 2nd Congress on Controversies in Thrombosis and Hemostasis November 05-07 2016 Spain.

Track-3: Translational Cardiology and Vascular Medicine

The goal of the Cardiac translational research is to accelerate translation of promising new fundamental research discoveries for the treatment of heart failure and arrhythmias through well-designed clinical trials that demonstrate efficacy and safety. Vascular medicine encompasses many different disease states. As the field of vascular medicine evolves, the scope of diseases being treated changes. Cardiac remodeling refers to the changes in size, shape, structure and physiology of the heart after injury to the myocardium. The injury is typically due to acute myocardial infarction. To characterize the increase in lipoprotein translation by hypothyroidism, adipocytes were prepared from control and hypothyroid rats. Whereas LPL synthesis was higher in hypothyroid adipocytes, with no change in mRNA levels, there was no increase in hormone-sensitive lipase (HSL) synthesis.

To determine whether a transacting translation regulatory factor was present, a cytoplasmic fraction was prepared from control and hypothyroid adipocytes, and added to an in vitro translation system containing the hLPL mRNA. Clinical outcomes with non-biologic therapy, given early in the course of the disease, are as good as with biologic therapies. Combinations of treatments are usually required to achieve rapid and sustained remission.

Related Conferences: 9th International Conference on Molecular and cellular cardiology August 22-24 2016, Brazil; 2nd International Conference and Exhibition on Pediatric Cardiology September 22-24 2016, USA; 12th World Cardiology Congress October 10-12 2016, UK; International Congress on Interventional Cardiology October 20-22, 2016 Italy; European Cardiology Congress October 24-26,2016,Spain; Gulf Arrhythmia Congress January 21-23,2016 UAE; 18th Tremblant Interventional Cardiology Meeting February 03-06,2016 Canada; 21st Mayo Clinical Annual Cardiology at Cancun February 22-26,2016 Mexico; Euroecho Imaging December 02-05,2016 Spain.

Track-4: Translational Therapeutics and Technologies

As Project moves from the research phase into the development, true technology transfer needs to take place. Therapeutic angiogenesis is an experimental area of treatment of ischemia, the condition which associated with decrease in blood supply to certain body organs. Hepatocellular carcinoma (HCC) is a common solid cancer and the third most frequent cause of cancer-related mortality worldwide Molecular targeted therapies are used for treating HCC.

Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases ranging from genetic disorders to HIV infection to various cancers. Proteomics has the ability to interrogate a variety of bio specimens for their protein contents and accurately measure the concentrations of these proteins. Deciphering DNA sequences is essential for virtually all branches of biological research.

Related Conferences:  3rd International Conference on Health Informatics and Technology June 27-29 2016,USA; International Conference on Precision Medicine November 03-05 2016, USA; International Conference and Exhibition on Medical Writing and Healthcare Communications April 28-29 2016,UAE; International Conference and Exhibition on Nano medicine and Nano Technology in Healthcare July 25-27 2016, Thailand; World Congress on Public Health and Nutrition March 10-12 2016, Spain; 13th Congress of European Association of Clinical Pharmacology and Therapeutics June 24-27 2017, Czech Republic; American Society for Clinical Pharmacology and Therapeutics Annual Meeting March 3-7,2016 USA; Antibody Engineering and Therapeutics December 07-10 2015, USA; 8th International Conference on Complement Therapeutics September 01-06 2015, Greece; 10th Annual Huntington’s Therapeutics February 23-26 2015, USA

Track-5: Translational Modeling of Efficacy and Safety

Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. Translation models describe the mathematical relationship between two or more languages. We call them models of translational equivalence because the main thing that they aim to predict is whether expressions in different languages have equivalent meanings.

The goal of translational research is to advance basic research and new technology toward clinical utility. Molecular diagnostics focuses primarily on nucleic acids. Rapid advances in molecular diagnostics both enable basic research and result in clinical diagnostic tests. The aim of translational research is to take the outcomes and innovations developed within the research context into clinical practice. A prototype is an early sample, model, or release of a product built to test a concept or process or to act as a thing to be replicated or learned from. Prototyping is the design verification phase of Product Development -- used to demonstrate or prove aspects of a design.  Prototyping is simply taking the design from the virtual, imaginary realm into the physical world.

Related Conferences: 3rd International Conference on Health Informatics and Technology June 27-29 2016,USA; International Conference on Precision Medicine November 03-05 2016, USA; International Conference and Exhibition on Medical Writing and Healthcare Communications April 28-29 2016,UAE; International Conference and Exhibition on Nano medicine and Nano Technology in Healthcare July 25-27 2016, Thailand; World Congress on Public Health and Nutrition March 10-12 2016, Spain; 3rd Annual Congress of European Society on Translational Medicine September 01-04 ,Austria; Translational Sciences 2015 Meeting, USA; Breast Cancer Symposium 2015 September 25-27 ,USA; 4th International Congress on Immunotherapy in Pediatric Oncology September 25-26,2015 USA; Romanian Society of Genetic Congress October 8-10 2015, Romania.

Track-6: Clinical Epidemiology

Epidemiology is the science that studies the patterns, causes, and effects of health and disease conditions in defined populations. The Clinical Epidemiology area of interest is the largest of the 12 areas of interest in the department of epidemiology. The Institute of Circulatory and Respiratory Health supports research into causes, mechanisms, prevention, screening, diagnosis, treatment, support systems, and palliation for a wide range of conditions associated with the heart, lung, brain (stroke), blood, blood vessels, critical care and sleep. Emergency medicine is a medical specialty involving care for adult and pediatric patients with acute illnesses or injuries that require immediate medical attention.

The advent of ever more sophisticated molecular manipulation techniques has made it clear that cellular systems are far more complex and dynamic than previously thought. At the same time, experimental techniques are providing an almost overwhelming amount of new data. The computational modeling is increasingly apparent that linking molecular and cellular structure to function will require the use of new computational tools. Many pregnancies have led to maternal mortality and maternal morbidity Maternal-fetal medicine (MFM) is the branch of obstetrics that focuses on the medical and surgical management of high-risk pregnancies.

Related Conferences: 4th International  Conference on Epidemiology and Public Health October 03-05 2016, UK; 2nd World Congress on Infectious Disease August 25-27 2016, USA: 4th International Conference on Bacteriology and Infectious Disease May 16-18 2016,USA; 2nd International  Conference on Retrovirus and Novel Drugs June 30-July 01 2016, South Africa; 3rd International  Conference on HIV/AIDS, STDs and STIs November 30-December 02 2015 USA; Pediatric Infectious Disease in Critical Care September 28-30 2015 UK; 15th European AIDS Conference October 21-25 2015 Spain; 6th Africa Nutrition Epidemiology Conference July 21-23 2016, South Africa; 2nd International Conference on Epidemiology and Infectious Disease September 18-20 2015, China; Canadian Society for Epidemiology & Biostatistics National Student Conference June 1-4 2016,Canada.


Track-7: Translational of Animal Models to Clinic

 Pre-clinical studies using animal models play a very important role in the evaluation of efficacy and safety of new medical diagnostic devices before their use in human clinical studies. It provides an overview of the emerging role, results of pre-clinical studies and development, and evaluation of animal models for percutaneous cardiovascular intervention technologies for patients with symptomatic cardiovascular disease such as cardiac arrest or coronary heart disease. One prominent explanation is flawed preclinical research, in which the use and outcome of animal models is pivotal to bridge the translational gap to the clinic. Therefore, the selection of a validated and predictive animal model is essential to address the clinical question. In this review, the current challenges and limitations of animal models are discussed, with a focus on the fit-for-purpose validation.

Animal models are essential for translation of drug findings from bench to bedside. Hence, critical evaluation of the face and predictive validity of these models is important. Reversely, clinical bedside findings that were not predicted by animal testing should be back translated and used to refine the animal models. The translation of findings from bench to clinically relevant therapies is very complex. In fact, despite a full preclinical and clinical trial package, the large majority of drugs with initial phases based on translational-laboratory based discoveries actually fail to complete the development process. A lack of efficacy, side-effects, inappropriate doses, and pharmacokinetics are just a few of the various reasons for this failure.

Related Conferences: 2nd International Conference on  Pharmacology  and  Ethan pharmacology, May 2-4 ,2016, USA; International  Conference on  Clinical Chemistry and Laboratory Medicine  May 2-3 ,2016,USA; 3rd International  Conference  on Pharmacology, August 8-10,2016 UK; 2nd  International  Conference  on  Clinical Trials ,August 22-24 ,2016, USA; 3rd International  Conference  on  Clinical Pharmacy December 7-9 ,2015, USA; American College Clinical Pharmacology Annual Meeting, September 27-29 ,2015, USA; The 7th Aquatic Animal Models of Human Disease Conference, December 13-18, 2014, USA; Animal Model For Human Health Conference, June7-8,2016 Poland; Predictive Preclinical Models in Oncology ,March 7-9 ,2016,USA;14th Annual PsychoPharmacology Update 2015 ,October 24 , 2015,USA .

Track-8:  Translational Oncology

Cancer remains the number two cause of disease-related mortality in the United States and worldwide. The molecular analysis of tumors has revealed significant variation in the pathways that drive tumor growth and metastasis.  Translational Oncology is concerned with the diagnosis of cancer (pathology), Therapy (e.g. surgery, chemotherapy, radiotherapy and other modalities), Follow-up of cancer patients after successful treatment, Palliative care of patients with terminal malignancies. Oncology depends on diagnostic tools like biopsy or removal of bits of the tumor tissue and examining it under the microscope. Other diagnostic tools include endoscopy for the gastrointestinal tract, imaging studies like X-rays, CT scanning, MRI scanning, ultrasound and other radiological techniques, Scintigraphy, Single Photon Emission Computed Tomography, Positron emission tomography and nuclear medicine techniques etc. 

Cancer is a genetic disease caused by the progressive accumulation of mutations in critical genes that control cell growth and cell differentiation. Completion of the Human Genome Project promises to revolutionize the practice of Medicine, especially genetic oncology care. The tremendous gains in the knowledge of the structure and function of human genes will surely impact the diagnosis, prognosis and treatment of cancer. Translational research also describes the process of moving knowledge obtained from clinical trials into a wider community or practice setting.

Related Conferences: International Conference on Oncology Nursing and Critical Care September 19-21 2016 USA; International Conference on Radiation Oncology September 26-28 2016, Spain; International Conference and Exhibition on Pediatric Oncology August 04-06 2016 Canada; International Conference on Neuro Oncology July 21-23,2016 Australia; International Conference and Exhibition on Surgical Oncology September 01-03 2016, Brazil; IMPAKT Brest Cancer Conference May 12-14,2016,Belgium; International Conference on Translational Research in Radio-Oncology & Physics for Health February 15-19 2016, Switzerland; Breast Cancer Symposium 2015 September 25-27 ,USA; 4th International Congress on Immunotherapy in Pediatric Oncology September 25-26,2015 USA.

Track-9: Immunology and Infectious Diseases

Clinical immunology is the study of diseases caused by disorders of the immune system (failure, aberrant action, and malignant growth of the cellular elements of the system). It also involves diseases of other systems, where immune reactions play a part in the pathology and clinical features. Many components of the immune system are actually cellular in nature and not associated with any specific organ but rather are embedded or circulating in various tissues located throughout the body. Immunotherapy is a new class of cancer treatment that works to harness the innate powers of the immune system to fight cancer. Because of the immune system's unique properties, these therapies may hold greater potential than current treatment approaches to fight cancer more powerfully, to offer longer-term protection against the disease, to come with fewer side effects, and to benefit more patients with more cancer types.

Scientists believe that for most people, Alzheimer's disease results from a combination of genetic, lifestyle and environmental factors that affect the brain over time. In Parkinson’s disease, cells that produce dopamine start to die. Dopamine is a chemical that helps you move normally. There is no known direct cause of Parkinson’s. One theory is that it may be hereditary. Other theories say exposure to pesticides and living in rural communities may cause it. he Human Immunodeficiency Virus (HIV) has infected approximately 1.5 million people in the United States. Type 1 translation research (basic research, methods development, and efficacy trials) has yielded multiple efficacious behavioral HIV prevention programs. Type 2 translation research (dissemination and effectiveness studies) has been less prevalent or successful.

Related Conferences: 2nd International Conference on Neuro immunology and Therapeutics March 31-April 02 2016 USA; International Conference on Cancer Immunology and Immunotherapy July 28-30 2016 Australia; 4th International Conference and Exhibition on Immunology September 28-30 2015 USA; 2nd World Congress on Infectious Disease August 25-27 2016, USA: 4th International Conference on Bacteriology and Infectious Disease May 16-18 2016,USA; International Congress of Innate Immunity September 30- October 03 2016, Spain;2nd International Primary Immunodeficiency Congress November 05-06 2015, Hungary; Novel Immunotherapeutic Summit January 25-26 2016, USA; Pediatric Infectious Disease in Critical Care September 28-30 2015 UK; 15th European AIDS Conference October 21-25 2015 Spain

Track-10: Advances in Translational Medicine

Translational Medicine seeks to translate biological and molecular knowledge of disease and how drugs work into innovative development strategies that reduce the cost and increase the speed of delivering new medicines to the patients. Whole genome sequencing should not be confused with DNA profiling, which only determines the likelihood that genetic material came from a particular individual or group, and does not contain additional information on genetic relationships, origin or susceptibility to specific diseases.

A biomedical science is a broad field that encompasses a number of disciplines. The branch of biomedical sciences that involves the use of genetic information to cure a disease is called gene therapy. Cytogenetic and Cheminformatics along with gene therapy are the emerging areas in the biomedical research. The National Institutes of Health (NIH) is the world's largest biomedical research agency, with a 75-year record of responding to the nation's key medical challenges. Today, medical science is entering a revolutionary period marked by a shift in focus from acute to chronic diseases, rapidly escalating health care costs, a torrent of biological data generated by the sequencing of the human genome, and the development of advanced high-throughput technologies that allow for the study of vast molecular networks in health and disease. 

Related Conferences: 7th International Conference on Biomarker and Clinical Research November 28-30 2016, USA; 4th International Conference on Blood Malignancies and Treatment April 18-20 2016, UAE; International Conference and Expo on Molecular and Cancer Biomarkers Sep 15-17 2016, Germany; International Conference and Exhibition on Pediatric Oncology August 04-06 2016, Canada;3rd Indo Global Summit & Expo on Healthcare October 05-07 2015 India; 3rd Annual Congress of European Society on Translational Medicine September 01-04 ,Austria; Translational Sciences 2015 Meeting, USA; Breast Cancer Symposium 2015 September 25-27 ,USA; 4th International Congress on Immunotherapy in Pediatric Oncology September 25-26,2015 USA; Romanian Society of Genetic Congress October 8-10 2015, Romania.

 

Translational Medicine-2016 welcomes attendees, presenters, and exhibitors from all over the world to San Francisco, USA. We are delighted to invite you all to attend and register for the “5th International Conference on Translational Medicine which is going to be held during November 28-30 , 2016 at San Francisco, USA.

Translational Medicine-2016 conference will focus on the latest and exciting innovations in all areas of   research offering a unique opportunity for investigators across the globe to meet, network, and perceive new scientific innovations. This year’s Translational Medicine highlights the theme, “Insights of Translational research” which reflects the emerging progress being made in the field of translational medicine

Importance & Scope

Translational medicine is a rapidly growing discipline in biomedical research and aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative; "bench-to-bedside" approach. Within public health, translational medicine is focused on ensuring that proven strategies for disease treatment and prevention are actually implemented within the community

Science Translational Medicine publishes articles containing original, science-based research that report successful progress toward improvements in clinical medicine Included within the scope are a broad array of traditional medical specialties including (but not limited to) cardiovascular medicine, cancer, immunology, neurology, psychiatry, metabolic diseases, radiology and imaging. Approaches applicable to all stages of the translational process are appropriate: bioengineering, drug discovery, diagnostics, biomarkers, pharmacokinetics, drug delivery, gene therapy and regenerative medicine.

Members Associated with Translational Research

The National Centre for Advancing Translational Sciences (NCATS) at the National  Institutes of Health (NIH). NCATS involves incorporation of 5 existing programs that have a $720 million annual budget. NCATS was formed in order to focus on the development of innovative strategies to overcome identified bottlenecks in new drug development that currently take 13 years and cost over $1 billion dollars. The current approach relies on NIH-funded scientists to make basic science discoveries and compliment industries efforts to develop and capitalize on new therapies.

                                                           

Major Associations and Societies

  • Association for Clinical and Translational Sciences
  • International Society for Cardiovascular Translational Research
  • Central Society for Clinical and Translational Research
  • European Society for Translational Medicine
  • CHI Institute for Research and Innovation( Centre for Translational Research)
  • Johns Hopkins Institute for clinical and Translational Research

The Catholic Health Initiatives (CHI) Center for Translational Research (CTR) provides fully consented biospecimens and clinical data to researchers, facilitating the development of next-generation drugs, diagnostics and devices. Our state-of-the-art research facility and biorepository, coupled with our 100+ hospital network and three academic medical centers, is here to support your discovery, preclinical and product development programs.

                                                      

 

Companies Associated with Translational Research  ( Region wise)

                                                   

Translational Research Market

The UK has one of the excellent translational medicine (TM) systems in EU. Two types of biomedical research centres are playing critical roles for advancement of Translational research in the country i.e., Comprehensive BRCs and Specialist BRCs. These centres have boasted translation research in the country which is evident by increase in total number of clinical trials numbers i.e., 290 in 2005; have risen to more than 850 in 2009- 10.

Seventh Framework Program is a main source for research funding in EU, with a total budget of over € 50 billion (2007-2013), of which 12% was for health. FP7 gives an emphasis to projects related to translational research in infectious diseases, cancer, cardiovascular disease, diabetes/ obesity, and rare diseases.

Translational medicine is an emerging field in Austria. In the past few years, academics have undertaken initiatives for establishment of translational research infrastructure in Austria. The Austrian Science Fund (FWF) which is one of the main research funding bodies in Austria has started a translational Research Programme which is part of the BRIDGE Initiative, commissioned by the Federal Ministry for Transport, Innovation and Technology (BMVIT)

The National   Centre for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). NCATS is the vision of NIH director Francis S. Collins and involves incorporation of 5 existing programs that have a $720 million annual budget. NCATS was formed in order to focus on the development of innovative strategies to overcome identified bottlenecks in new drug development that currently take 13 years, have a >95% failure rate, and cost over $1 billion dollars.

South Korea has a translational education focus on meeting its demand for clinical trial educational demands. The government formed Korea National Enterprise for Clinical Trials (KoNECT) which has been operating nationwide education programs for clinical trial professionals since 2008 mainly through government funds.

                                                         

Hospitals Associated with Translational Research

·  Medstar Good Samaritan Hospital- Baltimore, USA

·  Floridal Hospital- Translational Research Institute- Florida, USA

·  Atlanta VA Medical Centre- Georgia

·  Kansas Medical Centre- Kansas City

·  Pennington Biomedical Research Centre –LA

·  Maine Medical Centre- Scarborough, ME

·  Medstar community Clinical Research Centre- Hyattsvillae, MD

·  Tufts Medical Centre- Boston

·  HealthPartners Riverside Clinic –Minnepolis

·  Nebraska Medical Centre-Omaha, NE

·  Tennessee Health Science Centre- Memphis

·  Cleveland Clinic- Clevelac, OH

                                        

Funds allotted for Translational Research

Translational Research in USA combines basic research with advanced technology platforms to develop potential lead compounds that can prevent, treat or cure disease. The Translational Researchers works closely with the Scripps Florida academic departments to bring translational approaches to bear on complex biological problems. The Translational Research Institute (TRI) includes the following components: Discovery Biology, Drug Metabolism and Pharmacokinetics (DMPK), TRI-Informatics, Lead Identification and HTS, and Medicinal Chemistry. Translational research means different things to different people, but it seems important to almost everyone. The National Institutes of Health (NIH) has made translational research a priority, forming centers of translational research at its institutes and launching the Clinical and Translational Science Award (CTSA) program in 2006. By 2012, the NIH expects to fund 60 such centers with a budget of $500 million per year.1 Besides academic centers, foundations, industry, disease-related organizations, and individual hospitals and health systems have also established translational research program.

                                  

Market Growth of Translational Research ( 10 years back)

Clinical and Translational Science (CTS) program started in 2006 with similar goals of promoting collaborations between academia, government and industry to transform medical research. There is a network of 60 CTS centers in 30 U.S. states and the District of Columbia. CTSA centers promote advances in community engagement , comparative effectiveness research , biostatistics, epidemiology and research design (BERD) ,and investigator initiated clinical research involving drugs or devices. 

                                                       

 Market Growth of Translational Research (Next 10 Years)

The market growth of translational research in the coming years is very high with the rapid growth of institutes and researchers in the field of translational medicine.

                                       

National Institute of Health (NIH) Funding

The Survey of Federal Funds for Research and Development is the primary source of information about federal funding for R&D in the United States. The survey is an annual census completed by the federal agencies that conduct R&D programs. Federal funds data are collected annually for 3 government fiscal years: the fiscal year just completed, the current fiscal year, and the next fiscal year.

                                            

 

Translational Medicine 2015

With the successes of the previous conferences, OMICS Group hosted the 4thInternational Conference on Translational Medicine during October 26-28, 2015 in Baltimore, USA with the theme Enhancing New Diagnostic Tools and Therapeutic Dimensions in Translational Medicine which was a great success where eminent keynote speakers from various reputed institutions and organizations with their esteemed presence addressed the gathering.

The meeting was carried out with various sessions, in which discussions were held on the following thought provoking scientific tracks:

  • Biomarkers in Translational Medicine
  •  Role of Translational Research in Blood Disorders
  •  Translational Cardiology and Vascular Medicine
  • Translational Therapeutics and Technologies
  •  Translational Modeling of Efficacy and Safety
  • Clinical Epidemiology
  • Translational of Animal Models to the Clinic
  •  Clinical and Translational Oncology
  •  Immunology and Infectious Diseases
  •  Advances in Translational Medicine

The conference commenced with the opening ceremony followed by series of lectures from the Honorable Guest and the members of the Keynote Forum. The adepts who promulgated the theme with their exquisite talk were:

  • Sergey Suchkov, I M Sechenov First Moscow State Medical University, Russia
  • Isabelle de Waziers, Paris Descartes University, France
  • Sevtap Savas, Memorial University of Newfoundland, Canada
  • Rajendra Bhimma, University of KwaZulu-Natal, South Africa
  • Alina Borkowska, Nicolaus Copernicus University in Toruń, Poland

OMICS International is glad to have the connoisseur from all across the world. We thank all the Speakers, Poster Participants, Delegates, Organizing Committee Members, Chairs and Co-chairs and the Moderator whose support made the conference a big success.

Translational Medicine -2015 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various newfangled topics related to the field of Translational Medicine.

With the huge optimistic response from scientific fraternity and renowned scientists across the world, OMICS International is glad to announce the commencement of the 5thInternational Conference on Translational Medicine during November 28-30, 2016, San Francisco, USA.

Let us meet again @ Translational Medicine-2016


Past Reports  Proceedings  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date November 28-30, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1
Poster Opportunity Available

Media Partners

Testimonials

Conferenceseries Destinations